Trials / Completed
CompletedNCT02247141
A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®
A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam® Given Via the Subcutaneous Route in Primary Antibody Deficient Patients.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Bio Products Laboratory · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary objective was to determine the efficacy of Human Normal Immunoglobulin (Subgam®) given subcutaneously by weekly infusion to patients with primary antibody deficiency. The secondary objective was to determine the safety of Subgam® given subcutaneously by weekly infusion to patients with primary antibody deficiency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Subgam® (Human Normal Immunoglobulin Solution) |
Timeline
- Start date
- 2000-06-01
- Primary completion
- 2005-01-01
- First posted
- 2014-09-23
- Last updated
- 2018-01-24
Locations
14 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02247141. Inclusion in this directory is not an endorsement.